Managed Care

 

Examining Costs of Chronic Conditions In a Medicaid Population

MANAGED CARE August 2002. © MediMedia USA
Peer-Reviewed

Examining Costs of Chronic Conditions In a Medicaid Population

Robert I. Garis, RPh, PhD
Assistant Professor, Department of Pharmaceutical and Administrative Sciences, School of Pharmacy and Allied Health Professions, Creighton University, Omaha
Kevin C. Farmer, PhD
Associate Professor, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City
MANAGED CARE August 2002. ©MediMedia USA

Robert I. Garis, RPh, PhD

Assistant Professor, Department of Pharmaceutical and Administrative Sciences, School of Pharmacy and Allied Health Professions, Creighton University, Omaha

Kevin C. Farmer, PhD

Associate Professor, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City

ABSTRACT

Purpose: To compare health care costs and their components in patients with chronic illnesses.

Design: Quasi-experimental retrospective database analysis of an integrated state-Medicaid dataset.

Methods: Nine chronic illnesses and 28 two-disease combinations were evaluated in 284,060 patients. Dependent variables were total cost and the component costs (hospital, physician, home health and medical supplies, and pharmacy). Statistical analysis included analysis of variance (ANOVA) and multiple analysis of variance (MANOVA).

Results: The nine chronic illnesses studied were: psychosis, depression, cardiovascular illness, congestive heart failure, diabetes, acid peptic illness, respiratory illness/ asthma, hypertension, and anxiety. Psychosis and depression patients had the highest mean yearly costs at $6,964 and $5,505, respectively. Highest component costs were mental health practitioners for psychosis and hospital costs for depression. All other conditions had significantly lower yearly costs. Component costs consisted primarily of pharmacy and hospital costs. Psychosis was a component in 5 of the 7 most costly chronic-disease concurrences. The highest disease-concurrence mean cost was for psychosis and depression ($18,318).

Conclusions: The unique resource needs of different chronic illnesses should be considered in benchmarking and evaluating chronic-disease management programs.

Key terms: comorbidity, Medicaid program, disease management, cost analysis.

Author correspondence:
Robert I. Garis, RPh, PhD
Creighton University
School of Pharmacy and Allied Health Professions
Omaha, NE 68178
E-mail: rgaris@creighton.edu

Sources of financial support: This manuscript was written while the corresponding author was a graduate student at the University of Oklahoma, School of Pharmacy. The work was supported by the University of Oklahoma, the American Foundation for Pharmaceutical Education, and a grant from the Graduate Student Association of the University of Oklahoma.

This paper has undergone peer review by appropriate members of Managed Care's Editorial Advisory Board.

Meetings

2014 Annual HEDIS® and Star Ratings Symposium Nashville, TN November 3–4, 2014
PCMH & Shared Savings ACO Leadership Summit Nashville, TN November 3–4, 2014
Medicare Risk Adjustment, Revenue Management, & Star Ratings Fort Lauderdale, FL November 12–14, 2014
World Orphan Drug Congress Europe 2014 Brussels, Belgium November 12–14, 2014
Healthcare Chief Medical Officer Forum Alexandria, VA November 13–14, 2014
Home Care Leadership Summit Atlanta, GA November 17–18, 2014
6th Semi-Annual Diagnostic Coverage and Reimbursement Conference Boston December 4–5, 2014
Customer Analytics & Engagement in Health Insurance Chicago December 4–5, 2014
Pharmaceutical and Biotech Clinical Quality Assurance Conference Alexandria, VA December 4–5, 2014
9th Semi-Annual Medical Device Coverage and Reimbursement Conference San Diego December 5, 2014
8th Annual Medical Device Clinical Trials Conference Chicago December 8–9, 2014
HealthIMPACT Southeast Tampa, FL January 23, 2015